Fatty Liver, Nutritional and Metabolic Disease
Conditions
Brief summary
A 2 x 2 cross-over dietary intervention trial designed to investigate the effects of low glycemic index (LGI) versus high glycemic index (HGI) diet on hepatic fat accumulation and gut microbiota composition in participants with NAFLD. Participants will be allocated randomly to a 2-week either high GI (HGI) or low GI (LGI) diet followed by a 4-week wash-out period and then the LGI or HGI diet, opposite to the first 2-weeks (N= 16).
Interventions
• Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
Sponsors
University of Nottingham
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* • Adult males and females aged from 18 to 65 years (balanced number). * Detected NAFLD by CAP-FibroScan™ \>288dB/m or by MRI-PDFF) \> 5% fat of liver weight. * Body mass index ≥ 25 kg/m2 * Have current moderate to high GI diet intake of ≥ 60 (Assessed from a completed 7-day food diary). * Abdominal obesity (Waist circumference \> 102 cm for males and \> 88 cm for females) * Able to give informed consent. * Able to undergo MRI/S and CAP-FibroScan™.
Exclusion criteria
* • Current smokers and excessive alcohol drinkers (\> 14 units/week). * Perimenopausal (irregular periods) women. * Participants with other liver abnormalities. * Participants with history of gastrointestinal surgeries, depression, eating disorders or difficulties. * Participants using pharmacologic agents for obesity or NAFLD. * Participants with type 1 diabetes. * Participants with type 2 diabetes on second line medications (eg GLP-1 analogues, sulfonylureas). * Participation in any other trial in the last 3 months. * Participants on any special diets (e.g. vegetarians). * Intolerance to foods included in the diet plan.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| liver fat content | At baseline | To assess the difference in liver fat content between LGI and HGI diet groups in participants with NAFLD using MRI/S |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood glucose level | At baseline | To assess the differences in blood glucose levels between LGI and HGI diet groups in participants with NAFLD using Horiba automated analyser. . |
| Blood insulin levels | At baseline | To assess the differences in blood insulin levels between LGI and HGI diet groups in participants with NAFLD using radioimmunoassay methods . |
| blood liver function tests | At baseline | To assess the differences in liver function biomarkers between LGI and HGI diet groups in participants with NAFLD using Horiba automated analyser. The blood liver function tests (LFTs) to be assessed are GGT(Gamma-Glutamyl Transferase), ALP(Alkaline Phosphatase), AST(Aspartate Amino Transferase), and ALT(Alanine Amino Transferase) |
| blood liver function test | 2 weeks | To assess the differences in liver function biomarkers between LGI and HGI diet groups in participants with NAFLD using Horiba automated analyser. The blood liver function tests (LFTs) to be assessed are GGT(Gamma-Glutamyl Transferase), ALP(Alkaline Phosphatase), AST(Aspartate Amino Transferase), and ALT(Alanine Amino Transferase) |
| blood lipids levels | At baseline | To assess the differences in blood lipids levels between LGI and HGI diet groups in participants with NAFLD using Horiba automated analyser. The blood lipids biomarkers to be assessed are Total Cholesterol, Free Fatty Acids, High-density lipoprotein, low-density lipoprotein, Triglycerides. |
| blood gut hormones levels | At baseline | To assess the differences in blood gut hormones levels between LGI and HGI diet groups in participants with NAFLD using radioimmunoassay (RIA) or Sandwich ELISA methods. The blood gut hormones to be assessed are Glucagon, Leptin, Ghrelin, PYY (Peptide YY), GLP-1 (Glucagon-like peptide 1). |
| Gut microbial composition | At baseline | To assess the difference in gut microbiota composition between LGI and HGI diet groups in participants with NAFLD using 16S sequencing of rRNA |
| Anthropometric measurements | At baseline | Weight in kg, Height in meters will be combined to report BMI kg/m\^2 or each study arm |
| Body composition Fat Mass | At baseline | Bio-electrical Impedance analysis (BIA) will be used to assess the body composition of fat mass %. |
| Body composition Muscle Mass | At baseline | Bio-electrical Impedance analysis (BIA) will be used to assess the body composition of muscle mass %. |
| Body composition Water Content | At baseline | Bio-electrical Impedance analysis (BIA) will be used to assess the body composition of water content %. |
| Visual analogue scales (VAS) | through study completion, an average of two weeks | Visual analogue scales (VAS) in 0 to 10 cm scale will be used to assess the participant's subjective appetite (hunger and fullness) during the each study arm. |
| Plasma Short Chain Fatty Acids (SCFAs) | At baseline | To investigate the differences in plasma SCFAs between LGI and HGI diet groups in participants with NAFLD. |
Countries
United Kingdom
Outcome results
None listed